Article · 31 Dec 2025
Conference abstract
Pharmacogenetics of cerebrovascular and cardiovascular risk factors in dementia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Alzheimerâ??s disease (AD) is a heterogeneous disorder with at least a tetravalent phenotype (neuropathological, neurobehavioral, age-related and gender-related components). Consequently, therapeutic intervention in dementia is polymodal, in order to modify the expression of all these complex phenotypes. AD patients present concomitant disorders including hypertension (20-30%), obesity (>20%), diabetes (24%), dyslipidemia (>40%) and metabolic disorders (>15%). Cardiovascular disorders (>40%), atherosclerosis (>60%) and different modalities of cerebrovascular damage (>60%) are frequent among patients with AD. Most of these concomitant anomalies may contribute to accelerate the dementia process. Pharmacogenetic studies in hypercholesterolemic patients with dementia treated with Atorvastatin (ATO)+LipoEsar (LIP) indicate that the therapeutic response to the combination of a conventional statin and a novel anti-atherosclerotic bioproduct is highly influenced by pathogenic and metabolic genes: (1) Cholesterol (CHO) levels are APOE-dependent. APOE-4/4 carriers exhibit the highest CHO levels. APOE-2/3, APOE-3/4 and APOE-4/4 carriers experience a gradual age-dependent decrease in CHO levels. (2) The therapeutic response of CHO to ATO+LIP is APOE-dependent. APOE-3/3 and APOE-3/4 carriers are the best responders and APOE-2/4 and APOE-4/4 carriers are the worst responders. (3) CYP2D6-EMs and IMs show a significant decrease in CHO levels in response to ATO+LIP, whereas PMs and UMs exhibit a poorer CHO lowering effect. (4) CYP2C9-EMs and IMs effectively respond to ATO+LIP, and CYP2C9-PMs do not respond. (5) CYP2C19-EMs and IMs significantly respond to ATO+LIP and PMs do not show any effect. (6) CYP3A4/5-EMs show a significant decrease in CHO levels after one month of treatment with ATO+LIP. Over 80% of CYP3A4/5-EMs responds to ATO+LIP, with an almost complete normalization of CHO levels. The effect in IMs is spectacular with over 90% of the patients experiencing a drastic reduction in CHO levels and 60% of RMs do not respond at all. Most of these effects can be explained on a pharmacogenetic basis.
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Pharmacogenomics & Pharmacoproteomics.
Article · 31 Dec 2025
Genetic Determinants of Individual Drug Response
Article · 31 Dec 2025
Genetic Variation in Drug Metabolism, Transport, and Treatment Response
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmacogenomics & Pharmacoproteomics
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Ramon Cacabelos”
